Jove
Visualize
Contact Us

Related Experiment Videos

Implications of the TIMI Trials.

A M Ross1

  • 1George Washington University, Washington, D.C.

Advances in Experimental Medicine and Biology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

The TIMI trials compared reperfusion strategies for heart attacks. Thrombolytic therapy with tissue plasminogen activator (TPA) showed higher reperfusion rates, while percutaneous coronary intervention (PCI) timing influenced outcomes and complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observations on Dental Caries.

International dental journal (Philadelphia, Pa.)·2023
Same author

Connecticut Valley Dental Society.

The Independent practitioner·2023
Same author

Theory vs. Facts.

The Independent practitioner·2023
Same author

A Class of Pulpless Teeth-Their Treatment.

The Independent practitioner·2023
Same author

Crown Work.

The Independent practitioner·2023
Same author

Epithelioma.

The Independent practitioner·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • The TIMI (Thrombolysis In Myocardial Infarction) trials are a series of studies evaluating treatments for acute myocardial infarction.
  • Previous research focused on reperfusion strategies and their impact on left ventricular (LV) function and clinical outcomes.

Purpose of the Study:

  • To compare the efficacy and safety of different reperfusion strategies in patients with ST-elevation myocardial infarction (STEMI).
  • To evaluate the impact of immediate versus delayed percutaneous coronary intervention (PCI) after thrombolytic therapy.
  • To assess the role of beta-blocker administration timing in conjunction with reperfusion therapy.

Main Methods:

  • TIMI I: Compared streptokinase with tissue plasminogen activator (TPA) for reperfusion.

Related Experiment Videos

  • TIMI IIA: Assessed immediate PCI versus delayed PCI (18-48 hours) post-TPA.
  • TIMI IIB: Compared routine early PCI with a conservative strategy, with secondary randomization to acute versus delayed beta-blocker administration.

    • Main Results:

    • TPA demonstrated higher reperfusion rates than streptokinase in TIMI I, with no significant difference in bleeding or clinical outcomes.
    • TIMI IIA showed equivalent LV function and mortality between immediate and delayed PCI groups, but more emergency CABG and bleeding with immediate PCI.
    • TIMI IIB revealed low mortality (≈5% at 2 weeks, sustained at 1 year) for both routine and conservative strategies, with less recurrent ischemia in the routine PCI group. Acute beta-blocker administration showed a trend towards decreased mortality.

    Conclusions:

    • Early reperfusion is crucial for improving LV function post-myocardial infarction.
    • The timing of PCI relative to thrombolysis impacts procedural outcomes and complications.
    • Both routine early PCI and conservative strategies yield similar long-term mortality, but routine PCI may reduce recurrent ischemia. Acute beta-blocker therapy warrants further investigation.